1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis program focuses on advancing discoveries toward clinical-stage milestones in regenerative medicine.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Applicants must have a clear California connection. Specifically, more than 50% of employees must be located in California, and the funded activities must be conducted in California (with limited exceptions). Confirm the full requirements in the official notice before applying.
Translational Research (California Institute for Regenerative Medicine - CIRM) is funded by California Institute for Regenerative Medicine (CIRM). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
Preclinical Development (PDEV) program is sponsored by California Institute for Regenerative Medicine (CIRM). The PDEV program supports preclinical development of stem cell-based and genetic therapies that offer potential for transformative clinical impact and address current barriers to patient access. This includes research on stem cell-derived retinal pigment epithelium (RPE) cells for treating maculopathies and supporting photoreceptors.
CLIN2 Awards: Funding Opportunity for Clinical Trials is sponsored by California Institute for Regenerative Medicine (CIRM). CIRM's CLIN2 Awards program supports the clinical development of stem cell-based and genetic therapy approaches for treating diseases with unmet medical needs. The program aims to expedite clinical development towards late-stage trials through innovative trial designs and strategies for market access and pre-commercialization.
The Merck Stimulating Innovative Research Grant Program 2026 includes a dedicated grant topic for artificial intelligence in cell culture media and process development, offering up to EUR 150,000 per year for up to 3 years. The program accelerates innovation through collaborative research, early engagement with industry experts, and translation of novel ideas into practical solutions. In 2026, priority areas also include in-vitro models for neuroinflammatory diseases (EUR 250,000/year for 2 years) and innovative approaches to contaminated materials remediation (EUR 150,000/year for 2 years). The two-stage application process begins with non-confidential submissions, followed by deep-dive workshops where finalists collaborate with Merck scientists and managers to jointly optimize proposals. The AI-specific grant focuses on applying machine learning and AI to optimize cell culture media formulation, bioprocess parameter optimization, and manufacturing quality control.
Clinical Translational Research Award (FY26 DMDRP) is sponsored by Congressionally Directed Medical Research Programs (CDMRP) - Duchenne Muscular Dystrophy Research Program (DMDRP). Supports translational studies beyond basic research with potential for near-term clinical impact. This includes small-scale preclinical and/or clinical research to support clinical trial readiness, and large, complex preclinical and/or clinical research (e.
DARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read articleThe FY2026 MEP Center State Competition ran in two rounds: eight states worth $139.1 million, then fourteen more worth $232.4 million, both closing August 21, 2026. That's 43 percent of the national network recompeted in twelve months, under a 50 percent non-federal cost share, while the administration's own budget request proposed eliminating the program. Here's what the award tables reveal, why incumbents are genuinely at risk, and how to position for the FY2027 wave.
Read articleOn August 14, 2026, the California Arts Council approved nearly $24.6 million across 1,200 grant awards. Buried in the release is a rare thing: before-and-after data showing exactly how much the ranked-priority bonus moved the pool. Small organizations went from 53% of applicants to 72% of awardees. Geography moved 19 points. First-time status barely moved at all. Here is what that means for the 2027 cycle.
Read article